Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

FDA OKs Halozyme's Hylenex; Baxter Planning Launch In 2006

Dec. 6, 2005

By Jennifer Boggs

FDA OKs Halozyme's Hylenex; Baxter Planning Launch In 2006

Dec. 6, 2005

By Jennifer Boggs

NeurogesX Adds $20M To Finish Pivotal Transacin Trials In Pain

Dec. 5, 2005

By Jennifer Boggs

NeurogesX Adds $20M To Finish Pivotal Transacin Trials In Pain

Dec. 5, 2005

By Jennifer Boggs

Lexicon, Genentech Sign $25M Drug Discovery Deal Expansion

Dec. 2, 2005

By Jennifer Boggs

Lexicon, Genentech Sign $25M Drug Discovery Deal Expansion

Dec. 2, 2005

By Jennifer Boggs

Actelion: Pursuing Bosentan In Pulmonary Fibrosis Despite Miss

Nov. 30, 2005

By Jennifer Boggs

Series A Brings CeNeRx $18.5M For Depression, Anxiety Drugs

Nov. 30, 2005

By Jennifer Boggs

Series A Brings CeNeRx $18.5M For Depression, Anxiety Drugs

Nov. 30, 2005

By Jennifer Boggs

Actelion: Pursuing Bosentan In Pulmonary Fibrosis Despite Miss

Nov. 30, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...